Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: a current view and opportunities for improvement.

Hawk ET, Habermann EB, Ford JG, Wenzel JA, Brahmer JR, Chen MS Jr, Jones LA, Hurd TC, Rogers LM, Nguyen LH, Ahluwalia JS, Fouad M, Vickers SM.

Cancer. 2014 Apr 1;120 Suppl 7:1113-21. doi: 10.1002/cncr.28571.

PMID:
24643649
3.

Perspectives on barriers and facilitators to minority recruitment for clinical trials among cancer center leaders, investigators, research staff, and referring clinicians: enhancing minority participation in clinical trials (EMPaCT).

Durant RW, Wenzel JA, Scarinci IC, Paterniti DA, Fouad MN, Hurd TC, Martin MY.

Cancer. 2014 Apr 1;120 Suppl 7:1097-105. doi: 10.1002/cncr.28574.

PMID:
24643647
5.

Surveillance of health status in minority communities - Racial and Ethnic Approaches to Community Health Across the U.S. (REACH U.S.) Risk Factor Survey, United States, 2009.

Liao Y, Bang D, Cosgrove S, Dulin R, Harris Z, Taylor A, White S, Yatabe G, Liburd L, Giles W; Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion.; Centers for Disease Control and Prevention (CDC)..

MMWR Surveill Summ. 2011 May 20;60(6):1-44.

PMID:
21597458
6.

Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Murthy VH, Krumholz HM, Gross CP.

JAMA. 2004 Jun 9;291(22):2720-6.

PMID:
15187053
7.

Geographic proximity and racial disparities in cancer clinical trial participation.

Kanarek NF, Tsai HL, Metzger-Gaud S, Damron D, Guseynova A, Klamerus JF, Rudin CM.

J Natl Compr Canc Netw. 2010 Dec;8(12):1343-51.

PMID:
21147901
8.

What factors influence minority use of National Cancer Institute-designated cancer centers?

Huang LC, Ma Y, Ngo JV, Rhoads KF.

Cancer. 2014 Feb 1;120(3):399-407. doi: 10.1002/cncr.28413.

PMID:
24452674
9.

The role of race and ethnicity in the State Children's Health Insurance Program (SCHIP) in four states: are there baseline disparities, and what do they mean for SCHIP?

Shone LP, Dick AW, Brach C, Kimminau KS, LaClair BJ, Shenkman EA, Col JF, Schaffer VA, Mulvihill F, Szilagyi PG, Klein JD, VanLandeghem K, Bronstein J.

Pediatrics. 2003 Dec;112(6 Pt 2):e521.

PMID:
14654674
10.

Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities.

Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP.

Ann Surg Oncol. 2007 Dec;14(12):3328-34.

PMID:
17682824
11.

Enrollment and Racial Disparities in Cancer Treatment Clinical Trials in North Carolina.

Zullig LL, Fortune-Britt AG, Rao S, Tyree SD, Godley PA, Carpenter WR.

N C Med J. 2016 Jan-Feb;77(1):52-8. doi: 10.18043/ncm.77.1.52.

PMID:
26763244
12.

An institutional strategy to increase minority recruitment to therapeutic trials.

Anwuri VV, Hall LE, Mathews K, Springer BC, Tappenden JR, Farria DM, Jackson S, Goodman MS, Eberlein TJ, Colditz GA.

Cancer Causes Control. 2013 Oct;24(10):1797-809. doi: 10.1007/s10552-013-0258-1.

PMID:
23846282
13.

The Institute of Medicine report "Unequal Treatment": implications for academic health centers.

Betancourt JR, Maina AW.

Mt Sinai J Med. 2004 Oct;71(5):314-21.

PMID:
15543432
14.

Equal participation of minority patients in U.S. national pediatric cancer clinical trials.

Bleyer WA, Tejeda HA, Murphy SB, Brawley OW, Smith MA, Ungerleider RS.

J Pediatr Hematol Oncol. 1997 Sep-Oct;19(5):423-7.

PMID:
9329463
15.

State-of-the-science of patient navigation as a strategy for enhancing minority clinical trial accrual.

Ghebre RG, Jones LA, Wenzel JA, Martin MY, Durant RW, Ford JG.

Cancer. 2014 Apr 1;120 Suppl 7:1122-30. doi: 10.1002/cncr.28570. Review.

PMID:
24643650
16.

Disparities in cancer care among racial and ethnic minorities.

Kolb B, Wallace AM, Hill D, Royce M.

Oncology (Williston Park). 2006 Sep;20(10):1256-61; discussion 1261, 1265, 1268-70. Review.

PMID:
17024873
17.

Assuring access to state-of-the-art care for U.S. minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program.

Kaluzny A, Brawley O, Garson-Angert D, Shaw J, Godley P, Warnecke R, Ford L.

J Natl Cancer Inst. 1993 Dec 1;85(23):1945-50.

PMID:
8230286
18.

Analysis of Maryland cancer patient participation in National Cancer Institute-supported cancer treatment clinical trials.

Baquet CR, Ellison GL, Mishra SI.

J Health Care Poor Underserved. 2009 May;20(2 Suppl):120-34.

PMID:
19711497
19.

A surveillance system for monitoring, public reporting, and improving minority access to cancer clinical trials.

Carpenter WR, Tyree S, Wu Y, Meyer AM, DiMartino L, Zullig L, Godley PA.

Clin Trials. 2012 Aug;9(4):426-35. doi: 10.1177/1740774512449531.

PMID:
22761398
20.

Impact and costs of targeted recruitment of minorities to the National Lung Screening Trial.

Duda C, Mahon I, Chen MH, Snyder B, Barr R, Chiles C, Falk R, Fishman EK, Gemmel D, Goldin JG, Brown K, Munden RF, Vydareny K, Aberle DR.

Clin Trials. 2011 Apr;8(2):214-23. doi: 10.1177/1740774510396742.

PMID:
21242173
Items per page

Supplemental Content

Support Center